ABOS

NASDAQ:ABOS

Acumen Pharmaceuticals, Inc.

Add to Watchlist
  • Stock

1.07

−5.31%

−0.50

USD last updated 27/07 01:51:33

Last Close

1.57

25/07 21:46

Market Cap

137.58M

Beta: -

Volume Today

129.63K

Avg: 100.61K

PE Ratio

−3.53

PFCF: −3.92

The article covers major developments in biotech and pharmaceuticals, including Merck's advancement of its HIV prevention pill MK-8527 to Phase 3 trials, Takeda's positive results for narcolepsy drug oveporexton, the FDA's release of 200+ drug rejection letters, rejections of advanced therapies by the FDA, concerns over GSK's Blenrep drug, and a collaboration between JCR and Acumen to address Alzheimer's drug delivery challenges.

drugdiscoverynews.com

JCR Pharmaceuticals and Acumen Pharmaceuticals announced a collaboration to develop a novel Alzheimer’s therapy using JCR’s J-Brain Cargo® technology, which enables blood-brain barrier penetration. The partnership includes upfront payments, milestone payments up to $555 million, and tiered royalties. The technology has been clinically validated with IZCARGO® in Japan.

businesswire.com

Citigroup initiated coverage on Acumen Pharmaceuticals (NASDAQ:ABOS) with a buy rating and $4.00 price target. UBS Group and HC Wainwright also issued buy ratings with revised price targets. The company reported Q2 earnings of ($0.48) EPS, exceeding estimates, and analysts predict -1.56 EPS for the year. Institutional investors including Susquehanna, Clune, and Jane Street adjusted their holdings in the fourth quarter.

defenseworld.net

Citigroup has initiated coverage on Acumen Pharmaceuticals (ABOS) with a 'Buy' rating, assigning a price target of $4.00 USD. Analysts' average target price is $8.75, implying a 667.54% upside from the current price of $1.14. The average brokerage recommendation is 1.4, indicating 'Buy' status.

gurufocus.com

The global Alzheimer's drugs market is projected to grow from USD 5.64 billion in 2025 to USD 11.34 billion by 2032, with a compound annual growth rate (CAGR) of 10.5%. The report by Coherent Market Insights analyzes market trends, competitive landscape, and key drivers, including technological innovation, pricing trends, and investment opportunities.

openpr.com

    Description

    Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorpora...Show More

    Earnings

    Earnings per Share (Estimate*)

    -8-6-4-22020-03-302021-03-312022-11-142024-05-142025-03-25

    Revenue (Estimate*)

    500K1M1.50M2020-03-302021-03-312022-11-142024-05-142025-03-25

    *Estimate based on analyst consensus